Value
6.9/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 8.2 |
| Analyst target | 6.0 |
CSTL · Why this verdict
Why Castle Biosciences (CSTL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Castle Biosciences shows a perfect recent earnings-beat streak and steep analyst-implied upside, with technicals reading as a pullback rather than a breakdown, but a sub-floor quality score, a failing Rule of 40 metric, and notable insider selling keep the engine's stance at exit.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Castle Biosciences carries an 81% analyst-implied upside per light coverage, and the engine's own risk/reward framework shows 57.2% upside versus 15.0% downside. Sentiment breakdown | Price appreciates toward the analyst target, narrowing the upside gap to under 40% within 12 months. | ↓Deteriorating |
| CounterLight analyst coverage, described as a dampened signal, means the 81% upside estimate rests on a thin sample of price targets and could be unreliable. | ||
Castle Biosciences has beaten consensus EPS estimates in 3 of its last reported quarters, averaging a 73.7% surprise. Earnings | The company beats consensus again at its next print, extending the beat streak. | ↓Deteriorating |
| CounterThe company's quality score of 3.1 sits below the engine's 4.0 floor, and a Rule of 40 score of -1 signals the beats are not yet translating into a durable growth-plus-margin profile. | ||
Although the stock sits below its 200-day moving average, the MA itself is still rising (+0.1%/30d), which the engine classifies as a pullback within an uptrend rather than confirmed technical weakness. Momentum breakdown | Price reclaims the 200-day moving average within 2 quarters, confirming the uptrend read was correct. | ↑Improving |
| CounterAn RSI of 73 flags an overbought bear-rally condition, suggesting the recent bounce could fail rather than confirm a genuine uptrend resumption. | ||
Insiders have sold $1.12 million in shares (0.153% of market cap), a notable-materiality signal the engine flags as a moderate insider-selling risk. Insider breakdown | Insider selling activity moderates to negligible levels ($0 net) over the next 90-day window. | →Stable |
| CounterSustained insider selling around this materiality threshold, paired with a sub-floor quality score, could reflect informed skepticism about the durability of recent earnings beats. | ||
Castle Biosciences' quality score of 3.1 sits below the engine's 4.0 minimum floor, triggering the exit recommendation despite a strong upside case and beat streak. Bear case | Quality score rises above 4.0 within 2 quarters if fundamentals genuinely strengthen enough to reverse the exit signal. | ↑Improving |
| CounterA Rule of 40 score of -1 and 'no competitive moat' both point to structural quality weakness rather than a temporary shortfall likely to reverse quickly. | ||
Castle Biosciences carries an 81% analyst-implied upside per light coverage, and the engine's own risk/reward framework shows 57.2% upside versus 15.0% downside.
↓DeterioratingSentiment breakdown
- Expectation
- Price appreciates toward the analyst target, narrowing the upside gap to under 40% within 12 months.
CounterLight analyst coverage, described as a dampened signal, means the 81% upside estimate rests on a thin sample of price targets and could be unreliable.
Castle Biosciences has beaten consensus EPS estimates in 3 of its last reported quarters, averaging a 73.7% surprise.
↓DeterioratingEarnings
- Expectation
- The company beats consensus again at its next print, extending the beat streak.
CounterThe company's quality score of 3.1 sits below the engine's 4.0 floor, and a Rule of 40 score of -1 signals the beats are not yet translating into a durable growth-plus-margin profile.
Although the stock sits below its 200-day moving average, the MA itself is still rising (+0.1%/30d), which the engine classifies as a pullback within an uptrend rather than confirmed technical weakness.
↑ImprovingMomentum breakdown
- Expectation
- Price reclaims the 200-day moving average within 2 quarters, confirming the uptrend read was correct.
CounterAn RSI of 73 flags an overbought bear-rally condition, suggesting the recent bounce could fail rather than confirm a genuine uptrend resumption.
Insiders have sold $1.12 million in shares (0.153% of market cap), a notable-materiality signal the engine flags as a moderate insider-selling risk.
→StableInsider breakdown
- Expectation
- Insider selling activity moderates to negligible levels ($0 net) over the next 90-day window.
CounterSustained insider selling around this materiality threshold, paired with a sub-floor quality score, could reflect informed skepticism about the durability of recent earnings beats.
Castle Biosciences' quality score of 3.1 sits below the engine's 4.0 minimum floor, triggering the exit recommendation despite a strong upside case and beat streak.
↑ImprovingBear case
- Expectation
- Quality score rises above 4.0 within 2 quarters if fundamentals genuinely strengthen enough to reverse the exit signal.
CounterA Rule of 40 score of -1 and 'no competitive moat' both point to structural quality weakness rather than a temporary shortfall likely to reverse quickly.
Per-dimension breakdown
Quality
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.0 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸Cash-burning: FCF -2% of revenue
- ▸Rule of 40: 18 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 7.5 |
- ▸Strong growth: 20% YoY
Momentum
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 5.4 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| news sentiment | 0.0 |
| Analyst rating | 5.0 |
| Price target | 8.0 |
- ▸Negative news sentiment (-1.00)
- ▸Analyst upside: 23%
Insider
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $8,537,677 (0.762% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.9 |
| quality rank | 3.3 |
| growth rank | 6.6 |
- ▸Conservative debt levels
Technical
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 2.1 |
| 52w position | 6.6 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.6 |
| days to cover | 5.4 |
| volatility | 2.0 |
| put call | 10.0 |
| implied vol | 1.1 |
| beta | 7.3 |
| debt equity | 9.7 |
- ▸High IV: 74%
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/0M
- ▸Earnings in 7 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- MOMENTUM:7.7>=5.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- ASYMMETRY:0.5<1.5@spot
- INSIDER:0.76%=EXTREME
- EARNINGS_PROXIMITY:7d<=7d
Warning (0)
none
Reward-to-Risk
0.53
Upside
+7.3%
Downside
13.7%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 62, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $1.1B<$5B
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's 0.5<1.5@spot outcome against Momentum at 7.7 and asymmetric R:R of 0.53.
The strongest dimensions are Momentum at 7.7, Growth at 7.5, and Catalyst at 7.0; the weakest are Technical at 2.9, Quality at 3.6, and Sentiment at 4.6. The V9 engine flagged 3 failed gates, producing an asymmetric reward-to-risk of 0.53 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Upside Valuation
Trip ifAnalyst-implied upside stays above 70% for 2 more quarterly refreshes without price appreciation.
- P2Earnings Beat Streak
Trip ifCastle Biosciences misses consensus EPS estimates by more than 10% at its next earnings report, breaking the current beat streak.
- P3Momentum Pullback Not Breakdown
Trip ifThe 200-day moving average slope falls below 0% over the next 30 days, or price fails to reclaim the 200-day moving average within 2 quarters.
- P4Insider Selling Risk
Trip ifNet insider selling value exceeds $2 million (0.3% of market cap) in the next 90-day window.
- P5Quality Floor Exit Signal
Trip ifThe quality score stays below 3.5 at the next quarterly refresh, confirming the exit signal remains valid.